JP6488003B2 - 安定なモンテルカスト溶液 - Google Patents

安定なモンテルカスト溶液 Download PDF

Info

Publication number
JP6488003B2
JP6488003B2 JP2017507675A JP2017507675A JP6488003B2 JP 6488003 B2 JP6488003 B2 JP 6488003B2 JP 2017507675 A JP2017507675 A JP 2017507675A JP 2017507675 A JP2017507675 A JP 2017507675A JP 6488003 B2 JP6488003 B2 JP 6488003B2
Authority
JP
Japan
Prior art keywords
solution
solution according
component
sodium
montelukast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017507675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515892A (ja
JP2017515892A5 (enExample
Inventor
クルナール バーヴサル
クルナール バーヴサル
レオン ポール グローザー
レオン ポール グローザー
フィリップ アクス
フィリップ アクス
Original Assignee
アールピー シーラー テクノロジーズ リミテッド ライアビリティ カンパニー
アールピー シーラー テクノロジーズ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アールピー シーラー テクノロジーズ リミテッド ライアビリティ カンパニー, アールピー シーラー テクノロジーズ リミテッド ライアビリティ カンパニー filed Critical アールピー シーラー テクノロジーズ リミテッド ライアビリティ カンパニー
Publication of JP2017515892A publication Critical patent/JP2017515892A/ja
Publication of JP2017515892A5 publication Critical patent/JP2017515892A5/ja
Application granted granted Critical
Publication of JP6488003B2 publication Critical patent/JP6488003B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017507675A 2014-04-25 2015-02-27 安定なモンテルカスト溶液 Expired - Fee Related JP6488003B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461984098P 2014-04-25 2014-04-25
US61/984,098 2014-04-25
PCT/US2015/017994 WO2015163978A1 (en) 2014-04-25 2015-02-27 A stable montelukast solution

Publications (3)

Publication Number Publication Date
JP2017515892A JP2017515892A (ja) 2017-06-15
JP2017515892A5 JP2017515892A5 (enExample) 2018-04-05
JP6488003B2 true JP6488003B2 (ja) 2019-03-20

Family

ID=54332972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017507675A Expired - Fee Related JP6488003B2 (ja) 2014-04-25 2015-02-27 安定なモンテルカスト溶液

Country Status (5)

Country Link
US (1) US9717684B2 (enExample)
EP (1) EP3134076A4 (enExample)
JP (1) JP6488003B2 (enExample)
CN (1) CN106456535B (enExample)
WO (1) WO2015163978A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017038732A1 (ja) * 2015-08-31 2017-03-09 大蔵製薬株式会社 モンテルカストの含水医薬製剤
CN108201525A (zh) * 2017-12-14 2018-06-26 重庆西南医院 一种促进孟鲁司特钠经鼻吸收促进剂及其使用方法
JP7049610B2 (ja) * 2018-05-21 2022-04-07 高田製薬株式会社 レボセチリジン固形製剤
CN108888602B (zh) * 2018-08-16 2021-04-06 海南锦瑞制药有限公司 一种孟鲁司特钠制剂及其制备方法
WO2020049505A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
WO2022103634A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Improved use of cannabinoids in the treatment of epilepsy
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1678139B1 (en) 2003-10-10 2011-08-31 Synhton B.V. Solid-state montelukast
BRPI0506610A (pt) 2004-02-03 2007-05-02 Chemagis Ltd montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico
WO2005089761A1 (en) 2004-03-17 2005-09-29 Pfizer Limited Combination for treating inflammatory diseases
TWI314454B (en) * 2005-01-04 2009-09-11 Ct Lab Inc An oral liquid pharmaceutical composition of leukotriene antagonists
WO2007005965A1 (en) * 2005-07-05 2007-01-11 Teva Paharmaceutical Industries Ltd. Purification of montelukast
CA2616129A1 (en) * 2005-07-20 2007-01-25 Dr. Reddy's Laboratories Ltd. Preparation of montelukast
US20090182148A1 (en) 2005-12-23 2009-07-16 Harmander Singh Pal Chawla Process for the manufacture of montelukast sodium
RS51330B (sr) * 2006-02-09 2011-02-28 Teva Pharmaceutical Industries Ltd. Stabilne farmaceutske formulacije montelukast natrijuma
IL181607A0 (en) 2006-02-27 2007-07-04 Chemagis Ltd Novel process for preparing montelukast and salts thereof
WO2007126865A2 (en) * 2006-03-30 2007-11-08 Patrin Pharma Leukotriene antagonists via nasal drug delivery
SI22382A (sl) 2006-10-26 2008-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek za pripravo montelukasta
EP2094665A4 (en) 2006-11-06 2010-11-24 Reddys Lab Ltd Dr PREPARATION OF MONTELUKAST AND ITS SALTS
WO2009117381A2 (en) * 2008-03-17 2009-09-24 Dr. Reddy's Laboratories Ltd. Preparation of montelukast and its salts
WO2010107404A1 (en) 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
TR201009398A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Fiziksel özellikleri geliştirilmiş tablet formülasyonları
WO2012066401A1 (en) 2010-11-16 2012-05-24 Lupin Limited Stable oral pharmaceutical compositions of montelukast
CN103781467B (zh) 2011-09-16 2016-08-31 辉凌公司 一种快速溶解药物组合物
KR20130076015A (ko) 2011-12-28 2013-07-08 주식회사 삼양바이오팜 높은 경도를 갖는 속붕정 및 이의 제조 방법
KR101418404B1 (ko) 2012-01-06 2014-07-10 한미약품 주식회사 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제
CN103239450B (zh) * 2012-02-07 2014-11-26 齐鲁制药有限公司 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法

Also Published As

Publication number Publication date
JP2017515892A (ja) 2017-06-15
EP3134076A4 (en) 2017-12-20
CN106456535B (zh) 2020-07-03
WO2015163978A1 (en) 2015-10-29
EP3134076A1 (en) 2017-03-01
CN106456535A (zh) 2017-02-22
US20150306031A1 (en) 2015-10-29
US9717684B2 (en) 2017-08-01

Similar Documents

Publication Publication Date Title
JP6488003B2 (ja) 安定なモンテルカスト溶液
JP7042015B2 (ja) 経口投与型コルチコステロイド組成物
TWI592159B (zh) 藥學組成物
ES2751329T3 (es) Proceso de fabricación de una forma de dosificación multifásica de rápida disolución liofilizada
US9789068B2 (en) Easily dosable solid preparation
AU2001273545A1 (en) Sildenafil citrate solid dispersions having high water solubility
KR101360526B1 (ko) 개선된 약력학적 특성을 갖는 약물 제형
CN103202822B (zh) 口腔内薄膜状基剂及制剂
CN110709064A (zh) 具有高单位面积重量的快速崩解的泡沫体薄片
EA027641B1 (ru) Продукт сомикронизации, включающий ацетат улипристала
ES2363390T3 (es) Película monocapa de desintegración rápida para la administración bucal de sustancias activas.
CN103282051A (zh) 口腔内崩解片剂
WO2024220974A1 (en) Rimegepant fast-dissolving films for oral administration
CN105555316B (zh) 通过二阶段的湿式制粒工序制备的崩解性颗粒组合物及含有该组合物的口腔内崩解片剂
KR20070118247A (ko) 쓴맛이 저감된 프란루카스트 수화물을 함유하는 제제
CN115054580A (zh) 大规格冻干口腔崩解片
JP2008094751A (ja) プランルカスト水和物含有医薬組成物
Bhoyar et al. Journal of Innovation and Invention in Pharmacy and Sciences (JIIPS)
EP2609911A1 (en) A novel process for preparing orally disintegrating flurbiprofen formulations
JP2007186444A (ja) プランルカスト含有製剤
TW201626989A (zh) 超高速崩解錠劑
TW201422224A (zh) 含有達泊西汀游離鹼的口腔用組成物
KR20140094762A (ko) 나프로닐을 포함하는 고체 분산체 및 이의 제조방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190222

R150 Certificate of patent or registration of utility model

Ref document number: 6488003

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees